Cyclosporine level at the second hour in pediatric hematopoietic stem cell transplant patients

Experimental and Clinical Transplantation

Volumn 9, Issue 5, 2011, Pages 329-335

  Balci, Yasemin Isik ^a   Tavil, Betul ^a   Karabulut, Erdem ^a   Kuskonmaz, Baris ^a   Kucukbayrak, Ozlem ^a   Akyol, Fatma ^a   Hascelik, Gulsen ^a   Cetin, Mualla ^a   Uckan, Duygu ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Adverse effects; Children; Cyclosporine; Hematopoietic stem cell transplant; Nephrotoxicity

Indexed keywords

BUSULFAN; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; FLUDARABINE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POTASSIUM; THYMOCYTE ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; AGE; APLASTIC ANEMIA; ARTICLE; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONGENITAL DYSERYTHROPOIETIC ANEMIA; CREATININE BLOOD LEVEL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; GINGIVA OVERGROWTH; GRAFT VERSUS HOST REACTION; GYNECOMASTIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOPHAGOCYTIC SYNDROME; HUMAN; HURLER SYNDROME; HYPERTRICHOSIS; IMMUNOSUPPRESSIVE TREATMENT; JUVENILE MYELOMONOCYTIC LEUKEMIA; LEUKODYSTROPHY; MALE; NEUROTOXICITY; OSTEOPOROSIS; PEDIATRICS; POTASSIUM BLOOD LEVEL; RETROSPECTIVE STUDY; SCHOOL CHILD; THALASSEMIA MAJOR;

ADMINISTRATION, ORAL; AGE FACTORS; BIOLOGICAL MARKERS; CHILD; CREATININE; CYCLOSPORINE; DRUG MONITORING; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; POTASSIUM; RETROSPECTIVE STUDIES; TURKEY;

EID: 80053943701     PISSN: 13040855     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Cole E, Keown P, Landsberg D, et al. Safety and tolerability of cyclosporine and cyclosporine microemulsion during 18 months of follow-up in stable renal transplant recipients: a report of the Canadian Neoral Renal Study Group. Transplantation. 1998;65:505-510.
2. Christians U, Sewing Kf. Cyclosporin metabolism in transplant patients. Pharmacol Ther. 1993;57:291-345.
3. Beauchesne PR, Chung NS, Wasan KM. Cyclosporine A: a review of current oral and intravenous delivery systems. Drug Dev Ind Pharm. 2007;33:211-220.
4. Fortina Ab, Piaserico S, Alaibac M, et al. Skin disorders in patients transplanted in childhood. Transpl Int. 2005;18:360-365.
5. Campana C, Regazzi MB, Buggia I, Molinaro M. Clinically significant drug interactions with cyclosporin. An update. Clin Pharmacokinet. 1996;30:141-179.
6. Billaud EM. C2 versus C0 cyclosporine monitoring: Still not the end. Transplantation. 2005;80:542.
7. Duncan N, Craddock C. Optimizing the use of cyclosporin in allogeneic stem cell transplantation. Bone Marrow Transplant. 2006;38:169-174.
8. Barkholt L, Remberger M, Bodegard H, Ringden O, Bottiger Y. Cyclosporine A (CsA) 2-h concentrations vary between patients without correlation to graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant. 2007;40:683-689.
9. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLAmatched sibling donors. Transplantation. 1974;18:295-304.
10. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versushost syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204-217.
11. McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology. 1984;4(1):116-122.
12. National Cancer Institute NCI 2004. http://www.nci.nih.gov/cancerinfo/pdq/supportivecare/oral%20complications/healthprofessional.
13. Fellstrom B. Cyclosporine nephrotoxicity. Transplant Proc. 2004;36:220S-223S.
14. Kagawa Y, Sawada J, Yamada S, et al. Relationship between development of nephrotoxicity and blood concentration of cyclosporine A in bone-marrow transplanted recipients who received the continuous intravenous infusion. Biol Pharm Bull. 2003;26:1115-1119.
15. Wu MS, Yang CW, Bens M, Peng KC, Yu HM, Vandewalle A. Cyclosporine stimulates Na+-K+-Cl- cotransport activity in cultured mouse medullary thick ascending limb cells. Kidney Int. 2000;58:1652-1663.
16. Fleming Dr, Ouseph R, Herrington J. Hyperkalemia associated with cyclosporine (CsA) use in bone marrow transplantation. Bone Marrow Transplant. 1997;19:289-291.
17. Higgins R, Ramaiyan K, Dasgupta T, et al. Hyponatraemia and hyperkalaemia are more frequent in renal transplant recipients treated with tacrolimus than with cyclosporin. Further evidence for differences between cyclosporin and tacrolimus nephrotoxicities. Nephrol Dial Transplant. 2004;19:444-450.
18. Videla C, Vega J, Borja H. Hepatotoxicity associated with cyclosporine monitoring using C2 recommendations in adults renal recipients receiving ketoconazole. Transplant Proc. 2005;37:1574-1576.
19. Yee GC, Lennon TP, Gmur DJ, Kennedy MS, Deeg HJ. Agedependent cyclosporine: pharmacokinetics in marrow transplant recipients. Clin Pharmacol Ther. 1986;40:438-443.
20. Halloran PF, Helms LM, Kung L, Noujaim J. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation. 1999;68:1356-1361.
21. Hendriks MP, Blijlevens NM, Schattenberg AV, Burger DM, Donnelly JP. Cyclosporine short infusion and C2 monitoring in haematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2006;38:521-525.
22. Schmidt H, Ehninger G, Dopfer R, et al. Correlation between low CSA plasma concentration and severity of acute GvHD in bone marrow transplantation. Blut. 1988;57:139-142.
23. Martin P, Bleyzac N, Souillet G, et al. Relationship between CsA trough blood concentration and severity of acute graft-versus-host disease after paediatric stem cell transplantation from matchedsibling or unrelated donors. Bone Marrow Transplant. 2003;32:777-784.
24. Fricker G, Drewe J, Huwyler J, Gutmann H, Beglinger C. Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br J Pharmacol. 1996;118:1841-1847.